J2G-MC-JZJB: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506782-56-00

Acronym

J2G-MC-JZJB

Enrollment

114

Registered

2024-05-16

Start date

2020-03-10

Completion date

Unknown

Last updated

2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RET-Mutant Medullary Thyroid Cancer

Brief summary

PFS by BICR

Interventions

DRUGSELPERCATINIB

DRUGCabozantinib

DRUGCABOZANTINIB

DRUGVANDETANIB

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS by BICR	—

Countries

Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026